Journal of the Formosan Medical Association
Volume 109, Issue 2 , Pages 113-119 , February 2010

Rosiglitazone Reduces Plasma Levels of Inflammatory and Hemostatic Biomarkers and Improves Global Endothelial Function in Habitual Heavy Smokers Without Diabetes Mellitus or Metabolic Syndrome

  • I-Chih Chen

      Affiliations

    • Division of Cardiology, Department of Internal Medicine, Tainan, Taiwan
    • Division of Cardiology, Department of Internal Medicine, Tainan Municipal Hospital, Tainan, Taiwan
    • ,
  • Ting-Hsing Chao

      Affiliations

    • Division of Cardiology, Department of Internal Medicine, Tainan, Taiwan
    • Cardiovascular Research Center, National Cheng Kung University College of Medicine and Hospital, Tainan, Taiwan
    • Department of Internal Medicine, National Cheng Kung University Hospital Dou-Liou Branch, Dou-Liou, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr Ting-Hsing Chao, Division of Cardiology, Department of Internal Medicine, National Cheng Kung University College of Medicine and Hospital, 138 Sheng Li Road, Tainan, Taiwan
    • ,
  • Wei-Chuan Tsai

      Affiliations

    • Division of Cardiology, Department of Internal Medicine, Tainan, Taiwan
    • Cardiovascular Research Center, National Cheng Kung University College of Medicine and Hospital, Tainan, Taiwan
    • ,
  • Yi-Heng Li

      Affiliations

    • Division of Cardiology, Department of Internal Medicine, Tainan, Taiwan
    • Cardiovascular Research Center, National Cheng Kung University College of Medicine and Hospital, Tainan, Taiwan

Received 18 February 2009 ,Revised 5 April 2009 ,Accepted 24 June 2009.

References 

  1. Raskin P , Rappaport EB , Cole ST , et al.   Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes . Diabetologia . 2000;43:278–284
  2. Parulkar AA , Pendergrass ML , Granda-Ayala R , et al.   Non-hypoglycemic effects of thiazolidinediones . Ann Intern Med . 2001;134:61–71
  3. Duan SZ , Usher MG , Mortensen RM . Peroxisome prolifer-ator-activated receptor-gamma-mediated effects in the vasculature . Circ Res . 2008;102:283–294
  4. Tseng CH , Huang TS . Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients . Diabetes Res Clin Pract . 2005;70:193–194
  5. Haffner SM , Greenberg AS , Weston WM , et al.   Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes melli-tus . Circulation . 2002;106:679–684
  6. Nordt TK , Peter K , Bode C , et al.   Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells . J Clin Endocrinol Metab . 2000;85:1563–1568
  7. Marx N , Froehlich J , Siam L , et al.   Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease . Arterioscler Thromb Vasc Biol . 2003;23:283–288
  8. Randriamboavonjy V , Pistrosch F , Bölck B , et al.   Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone . Circulation . 2008;117:52–60
  9. Yu J , Jin N , Wang G , et al.   Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease . Metabolism . 2007;56:1396–1401
  10. Rosmarakis ES , Falagas ME . Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials . Am Heart J . 2007;154:144–150
  11. Sorrentino SA , Bahlmann FH , Besler C , et al.   Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes melli-tus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone . Circulation . 2007;116:163–173
  12. Raji A , Seely EW , Bekins SA , et al.   Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients . Diabetes Care . 2003;26:172–178
  13. Wang TD , Chen WJ , Lin JW , et al.   Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome . Am J Cardiol . 2004;93:362–365
  14. Esposito K , Ciotola M , Carleo D , et al.   Effect of rosiglita-zone on endothelial function and inflammatory markers in patients with the metabolic syndrome . Diabetes Care . 2006;29:1071–1076
  15. Chinetti G , Fruchart JC , Staels B . Peroxisome proliferators-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation . Inflamm Res . 2000;49:497–505
  16. Inoue I , Katayama S , Takahashi K , et al.   Troglitazone has a scavenging effect on reactive oxygen species . Biochem Biophys Res Commun . 1997;235:113–116
  17. Chen Z , Ishibashi S , Perrey S , et al.   Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice. Pleiotropic effects on CD36 expression and HDL . Arterioscler Thromb Vasc Biol . 2001;21:372–377
  18. Li AC , Brown KK , Silvestre MJ , et al.   Peroxisome proliferators-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice . J Clin Invest . 2000;106:523–531
  19. Shiomi T , Tsutsui H , Hayashidani S , et al.   Pioglitazone, a peroxisome proliferators-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction . Circulation . 2002;106:3126–3132
  20. Willett WC , Green A , Stampfer MJ , et al.   Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes . N Engl J Med . 1987;317:1303–1309
  21. Li YH , Chen JH , Tsai WC , et al.   Synergic effect of thrombomodulin promoter-33G/A polymorphism and smoking on the onset of acute myocardial infarction . Thromb Haemost . 2002;87:86–91
  22. Teng JK , Lin LJ , Tsai LM , et al.   Acute myocardial infarction in young and very old Chinese adults: clinical and therapeutic implications . Int J Cardiol . 1994;44:29–36
  23. Zeiher AM , Schächinger V , Minners J . Long-term cigarette smoking impairs endothelium-dependent coronary artery vasodilator function . Circulation . 1995;92:1094–1100
  24. Tracy RP , Psaty BM , Macy E , et al.   Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects . Arterioscler Thromb Vasc Biol . 1997;17:2167–2176
  25. Blann AD , Steele C , McCollum CN . The influence of smoking on soluble adhesion molecules and endothelial cell markers . Thromb Res . 1997;85:433–438
  26. Sharp DS , Benowitz NL , Bath PM , et al.   Cigarette smoking sensitizes and desensitizes impedance-measured ADP-induced platelet aggregation in whole blood . Thromb Haemost . 1995;74:730–735
  27. Nakamura T , Ebihara I , Shimada N , et al.   Effect of cigarette smoking on plasma metalloproteinase-9 concentration . Clin Chim Acta . 1998;276:173–177
  28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults  . Executive summary of the third report of the National Cholesterol Education Program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . JAMA . 2001;285:2486–2497
  29. Chao TH , Tsai LM , Tsai WC , et al.   Effect of atrial fibrillation on pulmonary venous flow patterns assessed by Doppler transesophageal echocardiography . Chest . 2000;117:1546–1550
  30. Matthews DR , Hosker JP , Rudenski AS , et al.   Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man . Diabetologia . 1985;28:412–419
  31. Hijmering ML , Stroes ES , Pasterkamp G , et al.   Variability of flow mediated dilation: consequences for clinical application . Atherosclerosis . 2001;157:369–373
  32. De Roos NM , Bots ML , Schouten EG , et al.   Within-subject variability of flow-mediated vasodilation of the brachial artery in healthy men and women: implications for experimental studies . Ultrasound Med Biol . 2003;29:401–406
  33. Malik J , Wichterle D , Haas T , et al.   Repeatability of noninvasive surrogates of endothelial function . Am J Cardiol . 2004;94:693–696
  34. McEniery CM , Wallace S , Mackenzie IS , et al.   Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans . Hypertension . 2006;48:602–608
  35. Chowienczyk PJ , Kelly RP , MacCallum H , et al.   Photoplethysmographic assessment of pulse wave reflection . J Am Coll Cardiol . 1999;34:2007–2014
  36. Hayward CS , Kraidly M , Webb CM , et al.   Assessment of endothelial function using peripheral waveform analysis. A clinical application . J Am Coll Cardiol . 2002;40:521–528
  37. Wilkinson IB , Hall IR , MacCallum H , et al.   Pulse wave analysis. Clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function . Arterioscler Thromb Vasc Biol . 2002;22:147–152
  38. Gopaul NK , Manraj MD , Hébé A , et al.   Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism . Diabetologia . 2001;44:706–712
  39. Hetzel J , Balletshofer B , Rittig K , et al.   Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers . Arterioscler Thromb Vasc Biol . 2005;25:1804–1809
  40. Dandona P , Aljada A . A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis . Am J Cardiol . 2002;90:G27–G33
  41. Chao TH , Li YH , Chen JH , et al.   The 161TT genotype in the exon 6 of peroxisome proliferator-activated receptor γ gene is associated with premature acute myocardial infarction and increased lipid peroxidation in habitual heavy smokers . Clin Sci . 2004;107:461–466
  42. Amoruso A , Bardelli C , Gunella G , et al.   Quantification of PPAR-gamma protein in monocyte/macrophages from healthy smokers and non-smokers: a possible direct effect of nicotine . Life Sci . 2007;81:906–915
  43. Selvin E , Bolen S , Yeh HC , et al.   Cardiovascular outcomes in trials of oral diabetes medications: a systematic review . Arch Intern Med . 2008;168:2070–2080
  44. Monami M , Marchionni N , Mannucci E . Winners and losers at the rosiglitazone gamble. A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone . Diabetes Res Clin Pract . 2008;82:48–57

PII: S0929-6646(10)60031-9

doi: 10.1016/S0929-6646(10)60031-9

Journal of the Formosan Medical Association
Volume 109, Issue 2 , Pages 113-119 , February 2010

Article Tools